Tech Company Financing Transactions
Captain T Cell Funding Round
Captain T Cell, based in Berlin-Schönefeld, secured investment capital from SpringBoard Capital, Brandenburg Kapital and HIL-INVENT Ges.
Transaction Overview
Company Name
Announced On
11/17/2025
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to advance its autologous program CTC127 to clinical Phase I read-outs and its allogeneic program for off-the-shelf solid tumor treatments towards clinical trial readiness.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
Willy-Brandt-Platz 2
Berlin-Schönefeld, 12529
Germany
Berlin-Schönefeld, 12529
Germany
Phone
Undisclosed
Website
Email Address
Overview
Captain T Cell develops first-in-class, efficacy-enhanced T cell therapies against solid tumors that are not addressed by existing treatments. Captain T Cell generates next-generation TCR-T cells with enhanced persistence and the capacity to cope with the hostile tumor microenvironment of difficult-to-treat solid tumors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Felix Lorenz
Browse more venture capital transactions:
Prev: 11/17/2025: Skeletalis venture capital transaction
Next: 11/17/2025: SubImage venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs